UNIONDALE, NY / ACCESSWIRE / January 15, 2025 / Marquis Who's Who honors Jan M. Lundberg, PhD, for his expertise in pharmaceuticals and research. Dr. Lundberg has over 30 years of professional experience in the pharmaceutical industry.
Breakthroughs in the pharmaceutical industry have led to the creation of medications that improve the quality of life for millions. These developments are made possible through dedicated researchers determined to discover new methods for addressing debilitating diseases.
Dr. Lundberg is one researcher whose contributions extend from his prolific publications to his exceptional leadership at research firms. Even in retirement, he continues his efforts to develop medicines that address the medical needs of today's populations.
Lundberg's Extensive Academic Background
Dr. Lundberg's career journey began in academia. He completed coursework in medicine at the University of Gothenburg and earned a Doctor of Philosophy in pharmacology from Karolinska Institutet, both medical universities in Sweden. From 1993 to 1996, he did research and taught as a professor at Karolinska Institutet. In 2003, Dr. Lundberg was awarded an honorary doctorate from Uppsala University in Uppsala, Sweden.
Leading in the Pharmaceutical Industry
In 1996, Dr. Lundberg began taking greater leadership roles in pharmaceutical research when he became the head of preclinical research at Astra. He rose to the global head of discovery research position following Astra's merger with the Zeneca Group, becoming AstraZeneca in 1999. Dr. Lundberg would serve in this role until 2009. He also co-founded AerocrineAB, a biotech company.
From 2010 to 2018, Dr. Lundberg was the president and head of research and development at Lilly Research Labs at Eli Lilly and Company (now Lilly). In these roles, he achieved some of his most notable career achievements.
When Dr. Lundberg joined, Lilly faced a potential takeover from another pharmaceutical firm. He led the organization of a robust pipeline from internal research and development, including for tirzepatide (product name Mounjaro, Zepbound) for diabetes type 2 and obesity, ixekizumab (Taltz) for autoimmunity, donanemab (Kisunla) for Alzheimer's and abemaciclib (Verzenio) for breast cancer. This was supplemented by key external programs empagliflozin (Jardiance) oral agent for diabetes type 2. Mounjaro was awarded Prix Galien for best pharmaceutical product in 2023. Based on pipeline progress and record product launches, Lilly's share price has risen manyfold, and the company is now a top global pharma by market capitalization.
Advanced Expertise in the Nervous System
Dr. Lundberg's academic background and expertise in understanding neural transmission have informed his career decisions and bolstered his success. During his academic research, he discovered that nerve signaling occurs not only via single mediators but by multiple mediators called co-transmitters, a fundamentally new principle of how the nervous system works.
Dr. Lundberg has additionally contributed to knowledge and research within his field by authoring more than 500 publications in high-impact journals. These research achievements have been awarded the Fernström and Jahre science prizes.
A Commitment to Addressing Alzheimer's Disease
Another factor driving Dr. Lundberg's career has been his personal experience with Alzheimer's disease. After watching how his mother was affected by this disease, he decided to dedicate his support to Alzheimer's research and programs.
When Dr. Lundberg came to Lilly, he convinced the firm to continue its Alzheimer's programs, even though they had high failure rates. This has resulted in Kisunla, a drug that can slow the progression of dementia.
A Promising Future for Pharmaceutical Research
Looking to the future of health technologies and pharmacology, Dr. Lundberg is interested in the potential of developing artificial intelligence (AI) technology to streamline the research process.
"It's such a complex activity with all the different modalities you are dealing with - the complexity of human physiology and pathophysiology and all the global clinical trials done over the years," Dr. Lundberg states. "I think the whole pharmaceutical R&D is a perfect example of where artificial intelligence can have a huge impact on the future."
Lundberg's Continued Contributions
Since 2018, Dr. Lundberg has enjoyed a well-earned retirement. However, he continues contributing to his field through consulting work and board roles, in which he focuses on addressing debilitating diseases such as diabetes, Alzheimer's disease, autoimmune disorders and cancer.
In the coming years, Dr. Lundberg plans to continue supporting the development of medicines that address unmet medical needs. As his legacy of excellence in research and leadership continues to grow, the impact of his work will be carried through the patients helped by these crucial medicines.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms worldwide. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
Marquis Who's Who
Uniondale, NY
(844) 394 - 6946
info@marquiswhoswho.com
www.marquiswhoswho.com
SOURCE: Marquis Who's Who
View the original press release on accesswire.com